-
First Immunotherapy Approved for Breast Cancer
Medical oncologist Leisha A. Emens discusses the significance of the first U.S. Food and Drug Administration approval of an immunotherapy treatment for breast cancer.
by Anna Azvolinsky
-
An Uncommon Partnership
Through the Angiosarcoma Project, researchers are partnering with patients to learn about a rare cancer.
by Ashley P. Taylor
-
Non–Small Cell Lung Cancer Takes Center Stage
A trio of clinical trials at the AACR Annual Meeting spotlight new avenues for non-small cell lung cancer treatment.
by Brad Jones
-
A New Type of Drug Approval
At the AACR Annual Meeting, researchers and regulators discuss what it means to tie approval of an immunotherapy to tumors' molecular characteristics, not to their tissues of origin.
by Kate Yandell
-
Pembrolizumab Shows Further Promise for Melanoma
In a phase III clinical trial, pembrolizumab yielded a 75.4 percent recurrence-free survival rate after 12 months among patients whose stage III melanoma tumors had been fully resected.
by Brad Jones
-
A Book Club for Cancer Survivors and Caregivers
Share your experiences as we discuss “A Cure Within” in a Cancer Today Facebook group.
by Marci A. Landsmann
Previous |
Cancer Talk
Treating HER2-ultralow Breast Cancer
FDA approval expands treatment options for people with metastatic breast cancer that expresses minimal levels of HER2.
by Sandra Gordon
Lessons Learned as a Caregiver and PatientAfter caring for her husband during his cancer treatment, Miriam Díaz-Gilbert was prepared to face her DCIS diagnosis.
by Miriam Díaz-Gilbert
Screening Options for People With Dense BreastsReports on breast density inform women of their status but raise questions about what to do next.
by Robin Roenker
Injection Immunotherapies Get FDA ApprovalGiving immunotherapy drugs as injections, rather than intravenously, means patients can spend less time in the hospital or treatment center.
by Laura Gesualdi-Gilmore